文献速递炎症性肠病

硫唑嘌呤或托法替布作为激素应答性急性重度溃疡性结肠炎的维持治疗

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid-Responsive Acute Severe Ulcerative Colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2025-06-20

这项倾向评分匹配的回顾性队列研究纳入115例对静脉糖皮质激素应答的急性重度溃疡性结肠炎成人患者,比较硫唑嘌呤(65例)与托法替布(50例)维持治疗的疗效与安全性。1年无事件生存累积概率托法替布组为75.0%,硫唑嘌呤组为44.0%(log-rank p=0.01)。结论认为托法替布在1年维持治疗中比硫唑嘌呤更有效。

要点

  • 1年无事件生存累积概率:托法替布组75.0% vs 硫唑嘌呤组44.0%(log-rank p=0.01)。
  • 再住院率硫唑嘌呤组15.4% vs 托法替布组0%(p=0.003),硫唑嘌呤组更高。
  • 治疗升级率硫唑嘌呤组13.8% vs 托法替布组2.0%(p=0.02),硫唑嘌呤组更高。

核心结论

  • 托法替布在1年时作为激素应答性急性重度溃疡性结肠炎的维持治疗比硫唑嘌呤更有效。

研究设计与样本

  • 倾向评分匹配的回顾性队列研究,评估硫唑嘌呤与托法替布作为维持治疗在對靜脈糖皮質激素應答的成人急性重度潰瘍性結腸炎患者中的有效性与安全性。
  • 最终分析纳入115例患者,中位年龄38岁(IQR:28-49),女性54例(46.95%),硫唑嘌呤组65例,托法替布组50例。

主要发现

  • 1年无事件生存累积概率硫唑嘌呤组为44.0%,托法替布组为75.0%(log-rank p=0.01)。
  • 再住院率硫唑嘌呤组15.4% vs 托法替布组0%(p=0.003),硫唑嘌呤组显著更高。
  • 治疗升级率硫唑嘌呤组13.8% vs 托法替布组2.0%(p=0.02),硫唑嘌呤组显著更高。
  • 1年时,托法替布组达到症状缓解的患者比例高于硫唑嘌呤组(40.0% vs 23.1%;p=0.05)。
  • 1年时,托法替布组达到症状联合生物标志物缓解的比例与硫唑嘌呤组相比差异无统计学意义(22.0% vs 16.9%;p=0.49)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal maintenance therapy for patients with acute severe ulcerative colitis (ASUC) remains unclear. AIM: To evaluate the efficacy of azathioprine and tofacitinib in maintaining remission in patients with ASUC who respond to intravenous corticosteroids. METHODS: This propensity score-matched, retrospective cohort study evaluated the effectiveness and safety of azathioprine and tofacitinib as maintenance therapies in adult patients with ASUC responding to intravenous corticosteroids. We recorded rehospitalisation, corticosteroid reuse, therapeutic escalation, and colectomy. The primary endpoint was cumulative event-free survival at 1 year. Adverse events were documented in both treatment arms. RESULTS: We included 115 patients in the final analysis (median age: 38 years [IQR: 28-49]; 54 females [46.95%]; 65 on azathioprine, 50 on tofacitinib). The cumulative probability of event-free survival at 1 year was 44.0% with azathioprine and 75.0% with tofacitinib (log-rank p = 0.01). Rates of rehospitalisation (15.4% v. 0%; p = 0.003) and therapeutic escalation (13.8% v. 2.0%; p = 0.02) were significantly greater in the azathioprine group. More patients receiving tofacitinib achieved symptomatic remission (40.0% v. 23.1%; p = 0.05), and combined symptomatic and biomarker remission (22.0% v. 16.9%; p = 0.49) at 1 year than those receiving azathioprine. Adverse events were reported in 55 patients (47.8%). No patients in either group required discontinuation of therapy due to adverse events. CONCLUSION: Tofacitinib is more effective than azathioprine as maintenance therapy for steroid-responsive ASUC at 1 year.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Singh A, Bhardwaj A, Sharma R, et al. Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid-Responsive Acute Severe Ulcerative Colitis. Aliment Pharmacol Ther. 2025. PMID: 40538240. doi:10.1111/apt.70246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。